Immune evasion in cancer: Mechanistic basis and therapeutic strategies

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages S185-S198

  Vinay, Dass S ^a   Ryan, Elizabeth P ^b   Pawelec, Graham ^c   Talib, Wamidh H ^d   Stagg, John ^e   Elkord, Eyad ^f   Lichtor, Terry ^g   Decker, William K ^h   Whelan, Richard L ⁱ   Kumara, H M C Shantha ⁱ   Signori, Emanuela ^j   Honoki, Kanya ^k   Georgakilas, Alexandros G ^l   Amin, Amr ^m,n   Helferich, William G ^o   Boosani, Chandra S ^p   Guha, Gunjan ^q   Ciriolo, Maria Rosa ^r   Chen, Sophie ^s   Mohammed, Sulma I ^t   Azmi, Asfar S ^u   Keith, W Nicol ^v   Bilsland, Alan ^v   Bhakta, Dipita ^q   Halicka, Dorota ^w   Fujii, Hiromasa ^k   Aquilano, Katia ^r   Ashraf, S Salman ^m   Nowsheen, Somaira ^x   Yang, Xujuan ^o   Choi, Beom K ^y   Kwon, Byoung S ^a,y   more..

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^j INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^m UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

ⁿ CAIRO UNIVERSITY   (Egypt)

^o UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^p CREIGHTON UNIVERSITY   (United States)

^q SASTRA UNIVERSITY   (India)

^r UNIVERSITY OF ROME TOR VERGATA   (Italy)

^s Ovarian and Prostate Cancer Research Trust Laboratory   (United Kingdom)

^t Purdue University   (United States)

^u WAYNE STATE UNIVERSITY   (United States)

^v UNIVERSITY OF GLASGOW   (United Kingdom)

^w NEW YORK MEDICAL COLLEGE   (United States)

^x MAYO CLINIC   (United States)

^y National Cancer Center   (South Korea)

more..

Author keywords

Cancer; Immune evasion; T cells; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; NIVOLUMAB; PLANT MEDICINAL PRODUCT;

ADAPTIVE IMMUNITY; ADOPTIVE T CELL THERAPY; ANGIOGENESIS; ANTIGEN PRESENTATION; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CELL THERAPY; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG EFFICACY; GAMMA DELTA T LYMPHOCYTE; GENOMIC INSTABILITY; GLIOMA; HUMAN; IMMUNE EDITING; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOCYTE FUNCTION; METASTASIS POTENTIAL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR REJECTION; CARCINOGENESIS; DRUG EFFECTS; IMMUNE EVASION; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANTIGEN PRESENTATION; CARCINOGENESIS; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; NEOPLASMS; PHYTOCHEMICALS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84926160709     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.03.004     Document Type: Review

References (303)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Becker J.C., Andersen M.H., Schrama D., Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013, 62:1137-1148.
3. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7:651-658.
4. Blackwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2002, 357:539-545.
5. Rakoff-Nahoum S. Why cancer and inflammation. Yale J Biol Med 2007, 79:123-130.
6. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
7. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
8. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
9. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
10. de Martel C., Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009, 70:183-194.
11. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
12. Coussens L.M., Werb Z. Inflammatory cells and cancer: think different!. J Exp Med 2001, 193:F23-F26.
13. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
14. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
15. Sawnn J.B., Smyth M.J. Immune surveillance of tumors. J Clin Investig 2007, 117:1137-1146.
16. Shay J.W., Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-2933.
17. Jacobs J.F., Nierkens S., Figdor C.G., de Vries I.J., Adema G.J. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol 2012, 13:e32-e42.
18. Yokokawa J., Cereda V., Remondo C., Gulley J.L., Arlen P.M., Schlom J., et al. Enhanced functionality of CD4 + CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008, 14:1032-1040.
19. Gasparoto T.H., de Souza Malaspina T.S., Benevides L., de Melo E.J., Costa M.R., Damante J.H., et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 2010, 59:819-828.
20. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
21. Lee I., Wang L., Wells A.D., Dorf M.E., Ozkaynak E., Hancock W.W. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005, 201:1037-1044.
22. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
23. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
24. Shozaei F., Zhong C., Wu X., Yu L., Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008, 18:372-378.
25. Ostrand-Rosenberg S., Sinha P., Chornoguz O., Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother 2012, 61:1319-1325.
26. Seung L.P., Rowley D.A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995, 92:6254-6258.
27. Umansky V., Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 2012, 61:275-282.
28. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
29. van Kempen L.C., Ruiter D.J., van Muijen G.N., Coussens L.M. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 2003, 82:539-548.
30. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
31. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
32. Garrido F., Ruiz-Cabello F., Cabrera T., Pérez-Villar J.J., López-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18:89-95.
33. Hicklin D.J., Marincola F.M., Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999, 5:178-186.
34. Johnsen A.K., Templeton D.J., Sy M., Harding C.V. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999, 163:4224-4231.
35. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mulé J.J., Rosenberg S.A., et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993, 177:265-272.
36. Rotem-Yehudar R., Groettrup M., Soza A., Kloetzel P.M., Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 1996, 183:499-514.
37. Seliger B., Maeurer M.J., Ferrone S. TAP off-tumors on. Immunol Today 1997, 18:292-299.
38. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Investig 1996, 98:1633-1641.
39. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001, 186:153-168.
40. Lind M.H., Rozell B., Wallin R.P., van Hogerlinden M., Ljunggren H.G., Toftgård R., et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci USA 2004, 101:4972-4977.
41. Lin E.Y., Gouon-Evans V., Nguyen A.V., Pollard J.W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002, 7:147-162.
42. Klein S.C., Jücker M., Abts H., Tesch H. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV. Hematol Oncol 1995, 13:121-130.
43. Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994, 180:2371-2376.
44. Sotomayer E.M., Fu Y.X., Lopez-Cepero M., Herbert L., Jimenez J.J., Albarracin C., et al. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Downregulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol 1991, 147:2816-2823.
45. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
46. Gabrilovic D. Mechanisms and functional significance of tumor induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952.
47. McKallip R., Li R., Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999, 163:3718-3726.
48. Nakashima M., Sonoda K., Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999, 5:938-942.
49. Nakabayashi H., Nakashima M., Hara M., Toyonaga S., Yamada S.M., Park K.C., et al. Clinic-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape. Cancer Lett 2007, 246:182-189.
50. Sonoda K., Miyamoto S., Nakashima M., Wake N. The biological role of unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apotosis. Front Biosci 2008, 13:1106-1116.
51. Birkle S., Zeng G., Gao L., Yu R.K., Aubry J. Role of tumor-associated ganglisodes in cancer progression. Biochemie 2003, 85:455-463.
52. Muller A.J., Prendergast G.C. Marrying immunotherapy with chemotherapy: why say IDO?. Cancer Res 2005, 65:8065-8068.
53. Mills C.D., Shearer J., Evans R., Caldwell M.D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992, 149:2709-2714.
54. Boutard V., Havouis R., Fouqueray B., Philippe C., Moulinoux J.P., Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 1995, 155:2077-2084.
55. Xia Y., Yeddula N., Leblanc M., Ke E., Zhang Y., Oldfield E., et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 2012, 10.1038/ncb2428.
56. Prenderghast G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008, 27:3889-3900.
57. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009, 158. 638-351.
58. Kim H.J., Hawke N., Baldwin A.S. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006, 13:738-747.
59. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998, 95:1179-1183.
60. Maeda H., Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996, 156:73-78.
61. Driessens G., Kline J., Gajewski T.F. Costimulatory and inhibitory receptors in anti-tumor immunity. Immunol Rev 2009, 229:126-144.
62. Topalian S.L., Drake C.G., Pardoll D.M. Targeting PD-1/B7-H1 (PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 2012, 24:207-212.
63. French L.E., Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002, 12:51-55.
64. Slavin-Chiorini D.C., Catalfamo M., Kudo-Saito C., Hodge J.W., Scholm J., Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1(CD54) in target cells: implications for intrtumoral vaccine therapy. Cancer Gene Ther 2004, 11:665-680.
65. Chouaib S., meslin F., Thiery J., Mami-Chouaib F. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Clin Immunol 2009, 130:34-40.
66. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996, 26:2671-2679.
67. Lauritzsen G.F., Hofgaard P.O., Schenck K., Bogen B. Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 1998, 78:216-222.
68. Marusky A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805:105-117.
69. Miller F.R. Intratumor immunologic heterogeneity. Cancer Metastasis Rev 1982, 1:319-334.
70. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2322-2328.
71. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
72. Fiddler I.J., Hart I.R. Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217:998-1003.
73. Heppner G.H. Tumor heterogeneity. Cancer Res 1984, 44:2259-2265.
74. Nicolson G.L. Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev 1984, 3:25-42.
75. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935.
76. Ardiani A., Gameiro S.R., Palena C., Hamilton D.H., Kwilas A., King T.H., et al. Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Res 2014, 74:1945-1957.
77. Butler T.P., Gullino P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975, 35:512-516.
78. Tarin D., Price J.E., Kettlewell M.G., Souter R.G., Vass A.C., Crossley B., et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984, 44:3584-3592.
79. Chambers A.F., Naumov G.N., Varghese H.J., Nadkarni K.V., MacDonald I.C., Groom A.C. Critical steps in hematogenous metastasis: an overview. Surg Oncol Clin N Am 2001, 10:243-255.
80. Fiddler I.J. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999, 43:S3-S10.
81. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71.
82. Woodhouse E.C., Chuaqui R.F., Liotta L.A. General mechanisms of metastasis. Cancer 1997, 80:1529-1537.
83. Hunter K.W., Crawford N.P.S., Alsarraj J. Mechanisms of metastasis. Breast Cancer Res 2008, 10. 10.1186/bcr1988.
84. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
85. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
86. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
87. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
88. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Investig 2005, 115:44-55.
89. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
90. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
91. Branco-Price C., Zhang N., Schnelle M., Evans C., Katschinski D.M., Liao D., et al. Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell 2012, 21:52-65.
92. Kashiwagi S., Izumi Y., Gohongi T., Demou Z.N., Xu L., Huang P.L., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Investig 2005, 115:1816-1827.
93. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
94. Sceneay J., Chow M.T., Chen A., Halse H.M., Wong C.S., Andrews D.M., et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012, 72:3906-3911.
95. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, 18(August (8)).
96. Mackall C.L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000, 18:10-18.
97. Noonan F.P., Halliday F.J., Wall D.R., Clunie G.J.A. Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy. Cancer Res 1977, 37:2473-2480.
98. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11:215-233.
99. Loi S., Pommey S., Haibe-Kains B., Beavis P.A., Darcy P.K., Smyth M.J., et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 2013, 110:11091-11096.
100. Garnett C.T., Scholm J., Hodge J.W. Combination of docetaxel and recombinant vaccine enhances T-cell responses and anti-tumor activity; effects of docetaxel on immune enhancement. Clin Cancer Rev 2008, 14:3536-3544.
101. Hodge J.W., Garnett C.T., Farsaci B., Palena C., Tsang K.Y., Ferrone S., et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013, 133:624-636.
102. Uzawa A., Suzuki G., Kakata Y., Akashi M., Ohyama Hakanuma A. Radiosensitivity of CD45RO+ memory and CD45RO+ naïve T cells in culture. Radiat Res 1994, 137:25-33.
103. Ferguson R.M., Sutherland D.E., Kim T., Simmons R.L., Najarian J.S. The in vitro assessment of the immunesuppressive effect of fractionated total lymphoid irradiation in renal allotransplantation. Transplant Proc 1981, 13:1673-1675.
104. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814.
105. Kasid U., Suy S., Dent P., Whiteside T.L., Sturgill T.W. Activation of Raf by ionizing radiation. Nature 1996, 382:813-816.
106. Ifeadi V., Garnett-Benson C. Sub-lethal irradiation of colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signialing pathways. PLoS ONE 2012, 7:e31762.
107. Matsumura S., Demaria S. Up-regulation of the proinflammatory chemokine CXCL16 is a common response of tumors cells to ionization radiation. Radiat Res 2010, 173:418-425.
108. Garnett C.T., Palena C., Chakraborty M., Tsang K., Scholm J., Hodge J.W. Sub-lethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
109. Kumari A., Cacan E., Greer S.F., Garnett-Benson C. Turning T cells on: epigenetically enhanced effector T-cell activity following tumor cells irradiation. J Immunother Cancer 2013, 1:17. 10.1186/2052-1426-1-17.
110. Bernstein M., Garnett C.T., Zhang H., Velcich A., Wattenberg M., Gameiro S., et al. radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive anti-tumor immune interactions. Cancer Biother Radiopharm 2014, 29:153-161.
111. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Scholm J., Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64:4328-4337.
112. McBride W.H., Chiang C.S., Olson J.L., Wang C.C., Hong J.H., Pajonik F., et al. A sense of danger from radiation. Radiat Res 2004, 162:1-19.
113. Ishihara H., Tanaka I., Nemoto K., Tsuneoka K., Cheeramakara C., Yoshida K. Immediate-early, transient induction of the interleukin-1 beta gene in mouse spleen macrophages by ionizing radiation. J Radiat Res 1995, 36:112-124.
114. Ehlers G., Fridman M. Abscopal effect of radiation in papillary adenocarcinoma. Br J Radiol 1973, 46:220-222.
115. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima L., Liebes L., et al. Inozation radiation of distinct unrelated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
116. Durante M., Reppingen N., Held K.D. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 2013, (13):96-98. pii: S1471-4914.
117. Sylla P., Kirman I., Whelan R.L. Immunological advantages of advanced laparoscopy. Surg Clin N Am 2005, 85:1-18.
118. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
119. Lennard T.W., Shenton B.K., Borzotta A., Donnelly P.K., White M., Gerrie L.M., et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985, 72:771-776.
120. Whelan R.L., Franklin M., Holubar S.D., Donahue J., Fowler R., Munger C. Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc 2003, 17:972-978.
121. Zhang P., Cote A.L., de Vriess V.C., Usherwood E.J., Turk M.J. Induction of post-surgical immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 2007, 67:6468-6476.
122. Belanich M., Randall T., Pastor M.A., Kibitel J.T., Alas L.G., Dolan M.E., et al. Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 1996, 37:547-555.
123. Hotta T., Saito Y., Fujita H., Mikami T., Kurisu K., Kiya K., et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21:135-140.
124. Sleeman J., Steeg P.S. Cancer metastasis as a therapeutic target. Eur J Cancer 2010, 46:1177-1180.
125. Melief C.J., Toes R.E., Medema J.P., van der Burg S.H., Ossendorp F., Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2002, 75:235-282.
126. Itok K., Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006, 97:970-976.
127. Gilboa E. DC-based cancer vaccines. J Clin Investig 2007, 117:1195-1203.
128. Hodge J.W., Higgins J., Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and anti-tumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009, 27:4475-4482.
129. Scholm J., Hodge J.W., Palena C., Tsang K.Y., Jochems C., Greiner J.W. Therapeutic cancer vaccines. Adv Cancer Res 2014, 121:67-124.
130. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Investig 2007, 117:1466-1476.
131. Patyar S., Joshi R., Byrav D.S., Prakash A., Medhi B., Das B.K. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010, 17. doi:1186/1423-0127-17-21.
132. Xu J., Liu X.S., Zhou S.F., Wei M.Q. Combination of immunotherapy with anerobic bacteria for immunogene therapy of solid tumors. Gene Ther Mol Biol 2009, 13:36-52.
133. Andersen M.H. The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 2012, 61:1289-1297.
134. Byrne W.L., Mills K.H., Lederer J.A., O'Sullivan G.C. Targeting regulatory T cells in cancer. Cancer Res 2011, 71:6915-6920.
135. Rasku M.A., Clem A.L., Telang S., Taft B., Gettings K., Gragg H., et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6:12. 10.1186/1479-5876-6-12.
136. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
137. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010, 59:1593-1600.
138. Kim Y.S., Kim Y.J., Lee J.M., Kim E.K., Park Y.J., Choe S.K., et al. Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs. J Immunol 2012, 188:4226-4234.
139. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
140. Melancon M.P., Lu W., Huang Q., Thapa P., Zhou D., Ng C., et al. Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813. Biomaterials 2010, 31:6567-6573.
141. Barten R., Torkar M., Haude A., Trowsdale J., Wilson M.J. Divergent and convergent evolution of NK-cell receptors. Trends Immunol 2001, 22:52-57.
142. George T.C., Ortaldo J.R., Lemieux S., Kumar V., Bennett M. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J Immunol 1999, 163:1859-1867.
143. Schmidt S.V., Nino-Castro A.C., Schultze J.L. Regulatory dendritic cells: there is more than just immune activation. Front Immunol 2012, 3:274. 10.3389/fimmu.2012.00274.
144. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
145. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-872.
146. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11:1062-1070.
147. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 2012, 24:207-212.
148. Kim Y.S., Jung H.W., Choi J., Kwon B.S., Ham S.Y., Jung A.K., et al. Expression of AITR and AITR ligand in breast cancer patients. Oncol Rep 2007, 18:1189-1194.
149. Shashidharamurthy R., Bozeman E.N., Patel J., Kaur R., Meganathan J., Selvaraj P. Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. Med Res Rev 2012, 32:1197-1219.
150. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10:281-287.
151. Van den Eynde B.J., van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693.
152. Chen Y.T., Scanlan M.J., Sahin U., Türeci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Nat Acad Sci USA 1997, 94:1914-1918.
153. Ikeda H., Lethé B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-208.
154. Liu L., Lai S., Andrews L.G., Tollefsbol T.O. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004, 340:1-10.
155. Gu J., Kagawa S., Takakura M., Kyo S., Inoue M., Roth J.A., et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000, 60:5359-5364.
156. Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., Inoue M., et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000, 11:1397-1406.
157. Oji Y., Ogawa H., Tamaki H., Oka Y., Tsuboi A., Kim E.H., et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999, 90:194-204.
158. Oka Y., Elisseeva O.A., Tsuboi A., Ogawa H., Tamaki H., Li H., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51:99-107.
159. Oka Y., Tsuboi A., Kawakami M., Elisseeva O.A., Nakajima H., Udaka K., et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 2006, 13:2345-2352.
160. Wolchok J. How recent advances in immune therapy are changing the standard care for patients with metastatic melanoma. Ann Oncol 2012, 23. viii5-viii21.
161. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
162. Drake C.G., Antonarakis E.S. Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012, 22:197-202.
163. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with Paciltaxel and Carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blinded, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
164. Yang J.C., Hughes M., Kammula U. Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cells cancer as dissociated with enteritis and hypophysitis. J Immunother 2007, 30:825-830.
165. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
166. Melero I., Grimaldi A.M., Perez-Gracia J.L., Ascierto P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013, 19:997-1008.
167. + T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood 2011, 117:6952-6962.
168. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004, 172:464-474.
169. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. Int J Oncol 2012, 41:1181-1191.
170. Stagg J., Smyth M.J. Extracellular adenosine triphosphatase and adenosine in cancer. Oncogene 2010, 29:5346-5358.
171. Beavis P.A., Divisekera U., Paget C., Chow M.T., John L.B., Devaud C., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA 2013, 110:14711-14716.
172. Allard B., Pommey S., Smyth M.J., Stagg J. Targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Can Res 2013, 19(20):5626-5635.
173. Beavis P.A., Stagg J., Darcy P.K., Smyth M.J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012, 33:231-237.
174. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010, 107:1547-1552.
175. Stagg J., Divisekera U., Duret H., Sparwasser T., Teng M.W., Darcy P.K., et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011, 71:2892-2900.
176. Stagg J., Divisekera U., Duret H., Sparwasser T., Teng M.W., Darcy P.K., et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2011, 71:2892-2900.
177. Ohta A., Gorelik E., Prasad S.J., Ronchese F., Lukashev D., Wong M.K.K., et al. A2A adenosine receptor protects tumors from anti-tumor T cells. Proc Natl Acad Sci USA 2006, 103:13132-13137.
178. Gulley J.L., Madan R.A., Tsang K.Y., Jochems C., Marte J.L., Farsaci B., et al. Immune impact induced by PROSTVAC (PSA-TRICOM) a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2013, 2:133-141.
179. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Can Inst 2002, 94:805-818.
180. Rivoltini L., Kawakami Y., Sakaguchi K., Southwood S., Sette A., Robbins P.F., et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995, 154:2257-2265.
181. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997, 3:37-44.
182. Salgaller M.L., Afshar A., Marincola F.M., Rivoltini L., Kawakami Y., Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995, 55:4972-4979.
183. Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M.H., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
184. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999, 22:431-440.
185. Rice J., Ottensmeier C.H., Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108-120.
186. Lin M.A. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239:62-84.
187. Chiarella P., Fazio V.M., Signori E. Electroporation in DNA vaccination protocols against cancer. Curr Drug Metab 2013, 14(3):291-299.
188. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96:4262-4267.
189. Chiarella P., Massi E., De Robertis M., Sibilio A., Parrella P., Fazio V.M., et al. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther 2008, 8:1645-1657.
190. Lichtor T., Glick R.P., Lin H., O-Sullivan I., Cohen E.P. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer. Cancer Gene Ther 2005, 12:708-714.
191. Lichtor T., Glick R.P., Feldman L.A., Osawa G., Hardman J., O-Sullivan I., et al. Enhanced immunity to intracerebral breast cancer in mice immunized with a cDNA-based vaccine enriched for immunotherapeutic cells. J Immunother 2008, 31:18-27.
192. Nestle F.O. Dendritic cell vaccination for cancer therapy. Oncogene 2000, 19:6673-6679.
193. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 1254-1261.
194. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Scholm J., Sabzevari H. Inhibition of CD(+)CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cycloohosphamide. Blood 2005, 105:2862-2868.
195. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39:38-48.
196. Kantoff P.W., Higano C.S., Shore N.D., Berger E.D., Small E.J., Penson D.F., et al. Sipuleuciel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
197. Russo M., Spagnuolo C., Tedesco I., Russo G.L. Phytochemicals in cancer prevention and therapy: truth or dare?. Toxins 2010, 2:517-551.
198. Middleton E., Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 1992, 43:1167-1179.
199. Calder P.C. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2007, 77:327-335.
200. Dardenne M. Zinc and immune function. Eur J Clin Nutr 2002, 56:520-523.
201. Calder P.C., Kew S. The immune system: a target for functional foods?. Br J Nutr 2002, 88:S165-S176.
202. Hughes D.A. Dietary carotenoids and human immune function. Nutrition 2001, 10:823-827.
203. Kodama N., Komuta K., Nanba H. Effect of Maitake (Grifola frondosa) D-fraction on the activation of NK cells in cancer patients. J Med Food 2003, 6:371-377.
204. Cole B.F., Baron J.A., Sandler R.S., Haile R.W., Ahnen D.J., Bresalier R.S., et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007, 6:2351-2359.
205. Rock C.L. Multivitamin-multimineral supplements: who uses them?. Am J Clin Nutr 2007, 85:2775-2795.
206. Kim J., Denu R.A., Dollar B.A., Escalante L.E., Kuether J.P., Callander N.S., et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol 2012, 158:336-346.
207. Singh A.K., Gaur P., Das S.N. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions. Hum Immunol 2014, 75:250-260.
208. Ito Y., Vela J.L., Matsumura F., Hoshino H., Tyznik A., Lee H., et al. Helicobacter pylori cholesteryl α-glucosides contribute to its pathogenicity and immune response by natural killer T cells. PLOS ONE 2013, 8(12):e78191.
209. Jameson J., Witherden D., Havran W.L. T-cell effector mechanisms: gammadelta and CD1d-restricted subsets. Curr Opin Immunol 2003, 15:349-353.
210. Cheng C., Huang C., Ma T.T., Bian E.B., He Y., Zhang L., et al. SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages. Toxicol Lett 2014, 225:488-497.
211. Strauss L., Bergmann C., Gooding W., Johnson J.T., Whiteside T.L. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6301-6311.
212. Stewart C.A., Metheny H., Iida N., Smith L., Hanson M., Steinhagen F., et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Investig 2013, 123:4859-4874.
213. Whiteside T.L., Schuler P., Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012, 12:1383-1397.
214. Jia Y., Guan Q., Guo Y., Du C. Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola. Phytother Res 2012, 26:812-819.
215. Elkabets M., Ribeiro V.S., Dinarello C.A., Ostrand-Rosenberg S., Di Santo J.P., Apte R.N., et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010, 40:3347-3357.
216. Albulescu R., Codrici E., Popescu I.D., Mihai S., Necula L.G., Petrescu D., et al. Cytokine patterns in brain tumour progression. Mediat Inflamm 2013, 2013:979748.
217. Day S.D., Enos R.T., McClellan J.L., Steiner J.L., Velázquez K.T., Murphy E.A. Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine 2013, 64:454-462.
218. Fowler D.W., Copier J., Wilson N., Dalgleish A.G., Bodman-Smith M.D. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2012, 61:535-547.
219. Fu Z., Zuo Y., Li D., Xu W., Li D., Chen H., et al. The crosstalk: tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol 2013, 52:1760-1770.
220. Pahl J.H., Ruslan S.E., Buddingh E.P., Santos S.J., Szuhai K., Serra M., et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012, 18:432-441.
221. Martinet W., De Meyer I., Verheye S., Schrijvers D.M., Timmermans J.P., De Meyer G.R. Drug-induced macrophage autophagy in atherosclerosis: for better or worse?. Basic Res Cardiol 2013, 108:321.
222. Li N., Ma T., Han J., Zhou J., Wang J., Zhang J., et al. Increased apoptosis induction in CD4+CD25+ Foxp3+ T cells contributes to enhanced disease activity in patients with rheumatoid arthritis through Il-10 regulation. Eur Rev Med Pharmacol Sci 2014, 18:78-85.
223. Kawabe K., Lindsay D., Braitch M., Fahey A.J., Showe L., Constantinescu C.S. IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating PI3K/Akt pathway. Immunobiology 2012, 217:118-123.
224. Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013, 210:2057-2069.
225. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999, 93:1612-1621.
226. Naldini A., Pucci A., Bernini C., Carraro F. Regulation of angiogenesis by Th1- and Th2-type cytokines. Curr Pharm Des 2003, 9:511-519.
227. Larsen H., Muz B., Khong T.L., Feldmann M., Paleolog E.M. Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA. Arthritis Res Ther 2012, 14:R180. [Epub ahead of print].
228. Rankin E.B., Yu D., Jiang J., Shen H., Pearce E.J., Goldschmidt M.H., et al. An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther 2003, 2:687-693.
229. Caccamo N., Dieli F., Meraviglia S., Guggino G., Salerno A. Gammadelta T cell modulation in anticancer treatment. Curr Cancer Drug Targets 2010, 10:27-36.
230. Meraviglia S., Eberl M., Vermijlen D., Todaro M., Buccheri S., Cicero G., et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010, 161:290-297.
231. Gomes A.Q., Martins D.S., Silva-Santos B. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 2010, 70:10024-10027.
232. Wakita D., Sumida K., Iwakura Y., Nishikawa H., Ohkuri T., Chamoto K., et al. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 2010, 40:1927-1937.
233. Pakala R., Watanabe T., Benedict C.R. Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes. Cardiovasc Radiat Med 2002, 3:95-101.
234. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
235. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586.
236. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
237. Ferrarini M., Ferrero E., Dagna L., Poggi A., Zocchi M.R. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002, 23:14-18.
238. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
239. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
240. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001, 193:661-670.
241. Shen F., Li J.L., Cai W.S., Zhu G.H., Gu W.L., Jia L., et al. Interleukin-12 prevents colorectal cancer liver metastases in mice. OncoTargets Ther 2013, 6:523-526.
242. Thakur A., Schalk D., Sarkar S.H., Al-Khadimi Z., Sarkar F.H., Lum L.G. A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother 2012, 61:497-509.
243. Ye J., Ma C., Wang F., Hsueh E.C., Toth K., Huang Y., et al. Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res 2013, 73:6137-6148.
244. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006, 80:705-713.
245. Schoppmann S.F., Birner P., Stöckl J., Kalt R., Ullrich R., Caucig C., et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161:947-956.
246. Tsung K., Dolan J.P., Tsung Y.L., Norton J.A. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002, 62:5069-5075.
247. Wu X., Peng M., Huang B., Zhang H., Wang H., Huang B., et al. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013, 340:124-133.
248. Hayakawa Y., Sato-Matsushita M., Takeda K., Iwakura Y., Tahara H., Irimura T. Early activation and interferon-γ production of tumor-infiltrating mature CD27 high natural killer cells. Cancer Sci 2011, 102:1967-1971.
249. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Investig 2011, 121:4746-4757.
250. Schepetkin I.A., Quinn M.T. Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 2006, 6:317-333.
251. Jeff I.B., Yuan X., Sun L., Kassim R.M., Foday A.D., Zhou Y. Purification and in vitro anti-proliferative effect of novel neutral polysaccharides from Lentinus edodes. Int J Biol Macromol 2013, 52:99-106.
252. Zhao L., Xiao Y., Xiao N. Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells. Tumour Biol 2013, 34:1531-1536.
253. Wakshlag J.J., Balkman C.A., Morgan S.K., McEntee M.C. Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines. Am J Vet Res 2010, 71:89-96.
254. Yasui Y., Hosokawa M., Mikami N., Miyashita K., Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact 2011, 193:79-87.
255. Tanaka T., Kawamori T., Ohnishi M., Makita H., Mori H., Satoh K., et al. Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase. Carcinogenesis 1995, 16:2957-2963.
256. Sliva D., Loganathan J., Jiang J., Jedinak A., Lamb J.G., Terry C., et al. Mushroom Ganoderma lucidum prevents colitis-associated carcinogenesis in mice. PLoS ONE 2012, 7:e47873.
257. Joseph S., Sabulal B., George V., Antony K.R., Janardhanan K.K. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm 2011, 61:335-342.
258. Yang B., Xiao B., Sun T. Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice. Int J Biol Macromol 2013, 62:287-290.
259. Nishitani Y., Zhang L., Yoshida M., Azuma T., Kanazawa K., Hashimoto T., et al. Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLOS ONE 2013, 8:e62441.
260. Bisen P.S., Baghel R.K., Sanodiya B.S., Thakur G.S., Prasad G.B. Lentinus edodes: a macrofungus with pharmacological activities. Curr Med Chem 2010, 17:2419-2430.
261. Speranza L., Pesce M., Patruno A., Franceschelli S., de Lutiis M.A., Grilli A., et al. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs 2012, 10:890-899.
262. Hsieh T.C., Wu J.M. Suppression of proliferation and oxidative stress by extracts of Ganoderma lucidum in the ovarian cancer cell line OVCAR-3. Int J Mol Med 2011, 28:1065-1069.
263. Jiang J., Slivova V., Harvey K., Valachovicova T., Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 2004, 49:209-216.
264. Hsieh T.C., Wu P., Park S., Wu J.M. Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med 2006, 6:30.
265. Auyeung K.K., Law P.C., Ko J.K. Astragalus saponins induce apoptosis via an ERK-independent NF-kappaB signaling pathway in the human hepatocellular HepG2 cell line. Int J Mol Med 2009, 23:189-196.
266. Fang N., Li Q., Yu S., Zhang J., He L., Ronis M.J., et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. J Altern Complement Med 2006, 12:125-132.
267. Palozza P., Torelli C., Boninsegna A., Simone R., Catalano A., Mele M.C., et al. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett 2009, 283:108-117.
268. Gao Y., Gao H., Chan E., Tang W., Xu A., Yang H., et al. Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Investig 2005, 34:171-198.
269. Wang T., Xuan X., Li M., Gao P., Zheng Y., Zang W., et al. Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells. Diagn Pathol 2013, 8:179.
270. Wang K.P., Zhang Q.L., Liu Y., Wang J., Cheng Y., Zhang Y. Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes. J Agric Food Chem 2013, 61:9849-9858.
271. Kavitha K., Kowshik J., Kishore T.K., Baba A.B., Nagini S. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta 2013, 1830:4433-4444.
272. Wesolowska O., Wisniewski J., Bielawska-Pohl A., Paprocka M., Duarte N., Ferreira M.J., et al. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. Anticancer Res 2010, 30:4587-4593.
273. Yuen J.W., Gohel M.D., Au D.W. Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells. Nutr Cancer 2008, 60:109-119.
274. Gao Y., Tang W., Gao H., Chan E., Lan J., Zhou S. Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats. J Med Food 2004, 7:417-421.
275. Cao Q.Z., Lin Z.B. Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacol Sin 2004, 25:833-838.
276. Zhang L., Yang Y., Wang Y., Gao X. Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury. Pharmazie 2011, 66:144-150.
277. Sano B., Sugiyama Y., Kunieda K., Sano J., Saji S. Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model. Surg Today 2002, 32:503-509.
278. Kim D.H., Hossain M.A., Kim M.Y., Kim J.A., Yoon J.H., Suh H.S., et al. A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells. Int J Oncol 2013, 43:1915-1924.
279. Sliva D., Labarrere C., Slivova V., Sedlak M., Lloyd F.P., Ho N.W. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 2002, 298:603-612.
280. Liu X., Yang Y., Zhang X., Xu S., He S., Huang W., et al. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell. J Gastroenterol Hepatol 2010, 25:420-426.
281. Ren L., Perera C., Hemar Y. Antitumor activity of mushroom polysaccharides: a review. Food Funct 2012, 3:1118-1130.
282. Ogasawara M., Matsunaga T., Suzuki H. Differential effects of antioxidants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells. Biol Pharm Bull 2007, 30:200-204.
283. Polonini H.C., Lima L.L., Gonçalves K.M., do Carmo A.M., da Silva A.D., Raposo N.R. Photoprotective activity of resveratrol analogues. Bioorg Med Chem 2013, 21:964-968.
284. Mikstacka R., Ignatowicz E. Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer. Pol Merkur Lekarski 2010, 28:496-500.
285. Lu J., Sun L.X., Lin Z.B., Duan X.S., Ge Z.H., Xing E.H., et al. Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage. Phytother Res 2014, 28:200-206.
286. Ono Y., Hayashida T., Konagai A., Okazaki H., Miyao K., Kawachi S., et al. Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci 2012, 103:317-324.
287. Li Q., Bao J.M., Li X.L., Zhang T., Shen X.H. Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma. Chin Med J (Engl) 2012, 125:786-793.
288. Zong A., Cao H., Wang F. Anticancer polysaccharides from natural resources: a review of recent research. Carbohydr Polym 2012, 904:1395-1410.
289. Nagendraprabhu P., Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Investig New Drugs 2011, 29:207-224.
290. Choi Y.J., Yang K.M., Kim S.D., Yoo Y.H., Lee S.W., Seo S.Y., et al. Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells. Exp Ther Med 2012, 3:592-598.
291. Goodnow C.C., Sprent J., Fazekas de St Groth B., Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
292. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319:1676-1680.
293. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86:1159-1166.
294. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
295. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.
296. Schietinger A., Delrow J.J., Basom R.S., Blattman J.N., Greenberg P.D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335:723-727.
297. King C., Ilic A., Koelsch K., Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
298. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677-685.
299. Nagorsen D., Scheibenbogen C., Marincola F.M., Letsch A., Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003, 9:4296-4303.
300. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
301. Rosenberg S.A., Yang C., White D.E. Recombinant fowlfox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune response in patients with metastatic melanoma. Clin Cancer Res 2003, 9:2973-2980.
302. Choi B.K., Lee S.C., Lee M.J., Kim Y.H., Kim Y.W., Ryu K.W., et al. 4-1BB-based isolation and expansion of CD8+ T cells specific for self and non-self tumor antigens for adoptive T cell therapy. J Immunother 2014, 37:225-236.
303. Kalos M. Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. Cancer Immunol Immunother 2012, 61:127-135.